153559-49-0 | Bexarotene

Chemical type

• Retinoid X receptor (RXR) agonist

^[1]

• Synthetic retinoid

^[2]

Key properties

• Selective receptor agonist
• Investigated chemotherapeutic agent

^[1]

• Retinoid X receptor (RXR) agonist
• Reduces HA production by decreasing expression of HA synthases (HAS1, HAS2, HAS3) and CEMIP
• Induces apoptosis, differentiation, prevents multidrug resistance, inhibits angiogenesis and metastasis

^[2]

• Chemotherapy drug for high-risk liver hepatocellular carcinoma (HCC) patients
• Shown to have greater sensitivity in treating high-risk HCC patients
• Experimental use to inhibit liver cancer cell growth by downregulating specific lncRNAs (CASC19, LINC01138, NRAV, Z83851.1)

^[1]

• Treatment of cutaneous T-cell lymphoma (CTCL)
• Modulation of tumor microenvironment

^[2]

Classification by use

• Chemotherapy drugs
• Targeted cancer therapy agents

^[1]

• Anti-cancer agents
• Retinoids in dermatology and oncology

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma, Electronic Journal of Biotechnology, Volume 79, January 2026, 100701
2. [Cite:2] Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene, Cancers, 2025, 17(2), 324